Label: informationfortheuser
Apregia75mghardEFGcapsules
pregabalina
Readthelabelcarefullybeforestartingtotakethismedicine,becauseitcontainsimportantinformationforyou.
–Keepthislabel,asyoumayneedtorefertoitagain.
–Ifyouhaveanyquestions,consultyourdoctororpharmacist.
–Thismedicinehasbeenprescribedonlyforyou,andyoushouldnotgiveittootherswhomayhavethesamesymptomsasyou,asitmayharmthem.
–Ifyouexperienceadverseeffects,consultyourdoctororpharmacist,eveniftheyarenotlistedinthislabel.Seesection4.
Labelcontents
1.WhatisApregiaandwhatisitusedfor
2.WhatyouneedtoknowbeforestartingtotakeApregia
3.HowtotakeApregia
4.Adverseeffects
5.StorageofApregia
6.Contentsofthepackagingandadditionalinformation
Apregiabelongstoagroupofmedicinesthatareusedfortreatmentofepilepsy, neuropathic painandgeneralizedanxietydisorder(TAG)inadults.
Peripheral and central neuropathic pain:Pregabalinaisusedfortreatmentofchronic pain caused by nerve damage. There are various diseases that can cause peripheral neuropathic pain, such as diabetes or herpes. The sensation of pain could be described as heat, burning, pulsating pain, stabbing pain, acute pain, spasms, continuous pain, tingling, numbness and pins and needles sensation. Peripheral and central neuropathic pain could also be associated with mood changes, sleep disturbances, fatigue (tiredness) and may affect physical and social activity and overall quality of life.
Epilepsy:Pregabalinaisusedintreatmentofcertainclassesofepilepsy(partial seizureswithorwithoutsecondary generalization)inadults.Yourdoctorwillprescribepregabalinatotreatepilepsywhenyourcurrenttreatmentdoesnotcontrolthedisease.Youmusttakepregabalinainadditiontoyourcurrenttreatment.Pregabalinashouldnotbeadministeredalone,butshouldalwaysbeusedincombinationwithotherantiepilepticmedicines.
Generalized anxiety disorder:Pregabalinaisusedintreatmentofgeneralized anxiety disorder(TAG).ThesymptomsofTAGareexcessiveandprolongedanxietyandworrythataredifficulttocontrol.TAGmayalsoproducerestlessnessorsensationofexcitementornervousness,feelfatigued(tired)easily,havedifficultyconcentratingorstayingwiththemindblank,irritability,muscletensionorsleepdisturbance.Thisisdifferentfromdailylifestressandtensions.
Do not take Apregia
If you are allergic to pregabalin or any of the other ingredients in this medicine (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting to take Apregia.
Dependence
Some people may become dependent on pregabalin (need to continue taking the medicine). They may experience withdrawal effects when they stop using pregabalin (see section 3 “How to take Apregia” and “If you interrupt treatment with Apregia”). If you are concerned that you may become dependent on pregabalin, it is essential to consult your doctor.
If you notice any of the following signs while taking pregabalin, it could be a sign that you have become dependent:
- You need to take the medicine for a longer period than recommended by your doctor.
- You feel the need to take a higher dose than recommended.
- You are using the medicine for reasons other than those prescribed.
- You have made repeated and unsuccessful attempts to stop or control the use of the medicine.
- When you stop taking the medicine, you experience discomfort and feel better once you take the medicine again.
If you notice any of these signs, talk to your doctor to analyze the best assistance plan for you, including when it is appropriate to stop treatment and how to do it safely.
Children and adolescents
The safety and efficacy of pregabalin have not been established in children and adolescents (under 18 years old), so pregabalin should not be used in this age group.
Other medicines and Apregia
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medicine.
Pregabalin and certain medicines may interact with each other. When pregabalin is taken with certain medicines that have a sedative effect (including opioids), these effects may be potentiated, and may lead to respiratory insufficiency, coma, and death. The degree of dizziness, somnolence, and decreased concentration may increase if pregabalin is taken with other medicines that contain:
Pregabalin can be taken with oral contraceptives.
Taking Apregia with food, drinks, and alcohol
The pregabalin capsules can be taken with or without food.
It is recommended not to drink alcohol during pregabalin treatment.
Pregnancy and breastfeeding
Do not take pregabalin during pregnancy or lactation, unless your doctor has told you to. Using pregabalin during the first 3 months of pregnancy may cause congenital anomalies in the fetus that require medical treatment. In a study that reviewed data from women in Nordic countries who took pregabalin during the first 3 months of pregnancy, 6 out of 100 babies had such congenital anomalies. This contrasts with 4 out of 100 babies born to women not treated with pregabalin in the study. Facial abnormalities (cleft palate), eye abnormalities, nervous system abnormalities (including the brain), kidney abnormalities, and genital abnormalities have been reported.
Use a reliable contraceptive method in fertile women. If you are pregnant or breastfeeding, believe you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and operating machinery
Pregabalin may cause dizziness, somnolence, and decreased concentration. Do not drive, operate heavy machinery, or engage in other potentially hazardous activities until you know if this medicine affects your ability to perform these activities.
Followexactlytheadministrationinstructionsforthismedicationindicatedbyyourdoctor.Incaseofdoubt,consultyourdoctororpharmacistagain.Donottakemoremedicationthanprescribed.
Yourdoctorwilldeterminewhatdoseisadequateforyou.
Apregiaisavailableexclusivelyfororaluse.
Peripheral and central neuropathic pain, epilepsy, or generalized anxiety disorder:
Ifyouestimatethattheactionofpregabalinaistoostrongorweak,informyourdoctororpharmacist.
Ifyouareanelderlypatient(over65yearsold),takepregabalinanormally,exceptifyouhavekidneyproblems.
Yourdoctormayprescribeadifferentdosageordoseifyouhavekidneyproblems.
Swallowthecapsulewholewithwater.
Continuetakingpregabalinauntilyourdoctortellsyoutostoptakingit.
If you take more Apregia than you should:
Incaseofoverdoseoraccidentalingestion,consultyourdoctororpharmacistimmediatelyorvisitthenearestemergencyservice.Bringthepackageorbottleofcapsuleswithyou.YoucanalsocalltheToxicologicalInformationService,phone915620420,indicatingthemedicationandtheamountingested.
AsaresultofhavingtakenmoreApregiathanyoushouldhave,youmayfeeldrowsy,confused,agitated,orrestless.Clinicalreportshavealsoincludedseizuresandlossofconsciousness(coma).
If you forget to take Apregia:
Itisimportanttotakethecapsulesofpregabalinaregularlyatthesametimeeveryday.Ifyouforgettotakeadose,takeitassoonasyourememberwithoutdelayingthenextdose.Continuewiththenextdoseattheusualtime.Donottakeadoubledosetocompensateforthemisseddoses.
If you interrupt the treatment with Apregia:
Donotstoptakingpregabalinasuddenly.Ifyouwanttostoptakingpregabalina,talktoyourdoctorfirst.Hewilltellyouhowtodoit.Ifyouaregoingtostopthetreatment,itshouldbedonegraduallyoveraminimumofoneweek.
Oncethetreatmentwithpregabalinaisfinishedintheshortandlongterm,youshouldknowthatyoumayexperiencecertainadverseeffects,calledwithdrawaleffects.Theseeffectsincludesleepproblems,headache,nausea,anxietysensations,diarrhea,flu-likesymptoms,seizures,nervousness,depression,thoughtsofself-harmorsuicide,pain,sweating,anddizziness.Theseeffectsmayappearwithgreaterfrequencyorseverityifyouhavebeentakingpregabalinaforalongerperiodoftime.Ifyouexperiencewithdrawaleffects,visityourdoctor.
Ifyouhaveanyotherdoubtsabouttheuseofthismedication,askyourdoctororpharmacist.
Likeallmedicines,thismedicinecancausesideeffects,althoughnoteveryonewillexperiencethem.
Verycommon:canaffectmorethan1in10people
Common:canaffectupto1in10people
Uncommon:canaffectupto1in100people
Rare:canaffectupto1in1000people
Veryrare:canaffectupto1in10,000people
Frequencynotknown:cannotbeestimatedfromavailabledata
Onceyouhavefinishedashort-termtreatmentwithpregabalin,youshouldknowthatyoumayexperiencecertainsideeffects,calledwithdrawaleffects(see“IfyoustoptakingApregia”).
Ifyouexperienceswellinginthefaceoronthetongue,orifyourskinturnsredandyougetblisterorshedding,youshouldimmediatelyseekmedicalhelp.
Certainsideeffects,suchasdrowsiness,maybemorecommonsincepatientswithspinalcordinjurymaybetakingothermedicinestotreat,forexample,painorspasticity(muscletensionorrigidity),withsideeffectssimilartopregabalinsothattheintensityofthesesideeffectsmayincreasewhentakentogether.
Thefollowingadversereactionhasbeenreportedinpost-marketingexperience:difficultybreathing,shallowbreathing.
Reportingofadversereactions
Sincerinteanydroguserofpregabalinanyyourhavehadanyothermedicinestotatreattreatmentsandreportthemanyyourhavehadanyothermedicinesthatyouhavenoticedintheprescriptionandresponsibilitytoyourhealthandyourphysicianonceantoyourhealthandonceantoyourhealthandonceanyourhealthandonceantoyourhealthandyourhealthandonceantoyourhealthandyourhealthandonceantoyourhealthandyourhealthandonceantoyourhealthandyourhealthandonceantoyourhealthandyourhealthandonceantoyourhealthandyourhealthandonceantoyourh5. Conservation of Apregia Keepthismedicationoutofsightandoutofreachofchildren. Donotusethismedicationaftertheexpirationdatethatappearsonthecontainerafter CAD.Theexpirationdateisthelastdayofthemonthindicated. This medication does not require special storage conditions. Do not dispose of medications through the drains or trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the containers and medications you no longer need. In this way, you will help protect the environment. Composition of Apregia The active ingredient is pregabalina. Each hard capsule contains 75 mg of pregabalina. The other components are: pregelatinized starch (from maize), talco (E553b), dióxido de titanio (E171), gelatina (E441), óxido de hierro amarillo (E172), tinta negra de impresión - shellac (E904), óxido de hierro negro (E172) and propilenglicol (E1520). Appearance of the product and content of the container Hard capsules with the body and cap of yellowish-brown color. The cap of the capsule has black print «P75». The content of the capsule is a white or nearly white powder. The length of the capsule is 13.8–14.8 mm. Apregia is presented in blister packs containing 56 hard capsules. Holder of the marketing authorization and responsible for manufacturing Holder of the marketing authorization KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia Responsible for manufacturing KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany You can request more information about this medicine by contacting the local representative of the holder of the marketing authorization: KRKA Pharmaceutical, S.L., C/ Anabel Segura 10, Pta. Baja, Oficina 1, 28108 Alcobendas, Madrid, Spain Date of the last review of this leaflet: January 2024 The detailled information about this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es /. 6. Content of the container and additional information
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.